Andreas Schneeweiss

29PUBLICATIONS
247CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Rehabilitation engineeringMolecular targetsPredictive and prognostic markersTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (29)

|Apr 20, 2026
Durvalumab in Combination With Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: Long-Term Analysis From the GeparNuevo Trial.

|Jun 11, 2025
Correction: ENABLE-App-Based Digital Capture and Intervention of Patient-Reported Quality of Life, Adverse Events, and Treatment Satisfaction in Breast Cancer: Protocol for a Randomized Controlled Trial.

Thomas M Deutsch, Léa L Volmer, Manuel Feisst

|May 26, 2025
ENABLE-App-Based Digital Capture and Intervention of Patient-Reported Quality of Life, Adverse Events, and Treatment Satisfaction in Breast Cancer: Protocol for a Randomized Controlled Trial.

Thomas M Deutsch, Léa L Volmer, Manuel Feisst

|Feb 25, 2025
Neoadjuvant Paclitaxel/Olaparib in Comparison to Paclitaxel/Carboplatin in Patients with HER2-Negative Breast Cancer and HRD-Long-term Survival of the GeparOLA Study.

Peter A Fasching, Sabine Schmatloch, Jan Hauke

|Jan 30, 2025
Surrogate End Points for Overall Survival in Neoadjuvant Randomized Clinical Trials for Early Breast Cancer.

Fabio Conforti, Valentina Nekljudova, Isabella Sala

|Dec 23, 2024
Machine Learning to Predict the Individual Risk of Treatment-Relevant Toxicity for Patients With Breast Cancer Undergoing Neoadjuvant Systemic Treatment.

Lie Cai, Thomas M Deutsch, Chris Sidey-Gibbons

Pageof 5

Frequent Collaborators

14 joint publications

Peter Fasching

10 joint publications

Carsten Denkert

10 joint publications

Sibylle Loibl

10 joint publications

Michael Untch